Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Early PD (diagnosed within 3 years) | PADOVA Study - Genentech, Inc. (Roche)

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease

Objective

To evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Full Title

A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease

Status

Currently Enrolling

Who may be eligible to participate?

Male and female, 50 to 85 years of age, who were diagnosed with Parkinson's Disease within the last 6 months to 3 years at screening visit. Other exclusion criteria apply.

What does participation involve?

This study will consist of the following phases: screening, double-blind treatment, and safety follow-up. Participants who meet eligibility criteria will be randomly assigned (in a 1:1 ratio) in a blinded fashion to receive either placebo or the investigational treatment via intravenous infusion. The study duration will be at least 76 weeks for all participants.

Trial Phase

Phase 2b

ClinicalTrial.gov ID

NCT04777331

IRB Protocol Number
BN42358
Principal Investigator(s)
Pinky Agarwal, MD

Clinical Trial Categories

  • Parkinson's Disease
Sponsor(s)
Genentech, Inc. (Roche)
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Location

  • EvergreenHealth Clinical Trials
    12039 NE 128th Street, Suite 300
    Kirkland, WA 98034
    Main: 425-899-5385

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form